Number of eligible patients: CDEC discussed the uncertainty in the number of patients with reasonably intense to intense hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical experts consulted by CADTH indicated that some people that are categorized as getting mild or average condition might have a severe bleeding phenotype, https://hemgenix73107.vblogetin.com/41699613/5-easy-facts-about-hemgenix-described